Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

Group 1 - A class action was filed on behalf of investors who purchased or acquired Vistagen Therapeutics, Inc. common stock between April 1, 2024, and December 16, 2025 [1] - Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neuropsychiatric and neurological disorders [1]